

with other free SH-bearing molecules in the cell, such as cysteine and SH residues in proteins, yet their relatively low concentrations contribute only little towards changing the reduction potential of the cell upon oxidation. The reduction potential of cells was proposed to reflect their growth cycle. Accordingly, the reduction potential of proliferating cells (pH 7.0) is $E_{GSH} -240$ mV. Increased values ($E_{GSH} -200$ mV) represent differentiation, and a further oxidative shift to a higher value ($E_{GSH} -170$ mV) elicits apoptosis [27]. In this study, we aimed to examine the initial events leading to apoptosis upon allicin treatment and the dependence of the apoptotic pathway on the reduction potential of cells.

2. Materials and methods

Alliin was synthesized from L-cysteine and allyl bromide followed by H_2O_2 oxidation [30]. Allicin (purity ~98%) was produced by applying synthetic alliin onto an immobilized alliinase column and its concentration was determined by high-performance liquid chromatography, as previously described [31].

2,3-Bis (2-methoxy-4-nitro-5-sulphophenyl)-2 H-tetrazolium-5-carboxanilide (XTT) sodium salt; D,L-buthionine S, R-sulfoximine (BSO); cyclosporin A (CsA); N-acetyl-L-cysteine (NAC); 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB); metaphosphoric acid; phenazine methosulfate (PMS) and 2-vinylpyridine were purchased from Sigma Chemical (St. Louis, MO, USA).

2.1. Cell culture, cell viability and morphological studies.

HL60 human promyelocytic leukemia-derived cells and U937 human myelomonocytic cells were maintained in RPMI-1640 supplemented with 2 mM L-glutamine, 10% (v/v) fetal bovine serum and antibiotics. Cell viability was measured using the XTT assay, based on the reduction of tetrazolium salt to soluble formazan compounds by mitochondrial enzymes. Cells (15,000–20,000 cells/well) were seeded in a 96-well plate. After 16-h incubation with allicin, in the presence or absence of NAC (0.1–1.0 mM) or after 16 h incubation with BSO (0.1 mM) alone, 50 μ l of XTT/PMS mixture (50 μ M PMS, 0.1% XTT in medium) were added onto the cells. After an incubation period of 3–4 h at 37°C, the absorbance of the samples was measured in an enzyme-linked immunosorbent assay (ELISA) reader at 450 nm. SDS (1%, 10 μ l/well) was added to reference wells before adding the XTT/PMS solution.

HL60 cells (300,000/ml) were pretreated with CsA for 1 h. Cells were seeded in a 96-well plate (20,000 cells/well) in the presence of allicin. The viability was tested by the XTT assay. The analysis of apoptotic morphological changes was done by staining cells with Hoechst 33342 at 37°C for 30 min in medium, washing with phosphate-buffered saline (PBS) and examining by fluorescence microscopy. For evaluating DNA ladder formation, cellular DNA was

extracted from cells by ethanol precipitation of the phenol/chloroform extract [32]. After electrophoresis (5–10 μ g DNA/lane) on an agarose (2.5%) gel, DNA was visualized by ethidium bromide staining.

Mitochondrial membrane potential was measured by using the fluorescent dye, Mito Tracker Red CMXRos (Molecular Probes, Eugene, OR, USA) that accumulates selectively in active mitochondria. Cells were washed with medium, incubated with Mito-Tracker Red CMXRos for 30 min at 37°C, washed with PBS and examined under fluorescence microscopy (Olympus, Tokyo).

Mitochondria were prepared from cultured cells (5×10^7) as described elsewhere [33]. Cells were harvested and washed with PBS (600 g, 7 min). Cell pellets were suspended in 0.5 ml cold HIM buffer (200 mM mannitol, 70 mM sucrose, 1 mM EGTA, 10 mM HEPES-KOH buffer, pH 7.5) containing protease inhibitors, incubated 30 min on ice and homogenized by multiple passages through a 25-gauge needle (5/8 in.). Nuclei and unbroken cells were removed (1300 g, 8 min at 4°C). Protein and free SH were determined in the cytosol, supernatant (10,000 g, 30 min at 4°C) and in the mitochondria-enriched fraction (pellet, dissolved in HIM buffer containing 1% Triton X-100). Protein assay was done with the Biuret Reagent [34] or the BCA protein assay kit (Pierce, Rockford, IL, USA).

2.2. Cell cycle analysis

HL60 cells were pretreated with CsA (5 μ M, 1 h) and then cultured further for 20 h in the presence or absence of allicin. After harvesting, washing and resuspending in 0.25 ml PBS, an equal volume of 0.005% propidium iodide solution containing 0.01% heated-RNase A and 0.3% Triton X-100 was added. Cells were analyzed by flow cytometry using fluorescence-activated cell sorting (Becton Dickinson FACSscan Instrument using CellQuest software (BD Bioscience, San Jose, CA, USA)).

2.3. Electrophoresis and Western blot analysis

Cell pellet was resuspended in lysis buffers A or B [32]. Lysis buffer A (2 \times PBS, 0.1% sodium dodecyl sulfate (SDS), 1% Nonidet P-40, 0.5% sodium deoxycholate) containing protease inhibitors was used to analyze of caspases 3, 8 and 9. Lysis buffer B (250 mM sucrose, 20 mM HEPES-KOH buffer, pH 7.5, 10 mM KCl, 1.5 mM $MgCl_2$, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) containing protease inhibitors was used to analyze the presence of cytochrome c in the cytosol as described above (Section 2.2). After centrifugation (10,000g, 30 min, 4°C) the supernatant was separated by SDS-polyacrylamide gel electrophoresis using 15% gel and transferred electrophoretically onto a PVDF membrane (Du Pont, Boston, MA, USA). The membrane was incubated overnight at 4°C with the following antihuman antibodies: anti β -actin (Sigma-Aldrich), anti-caspase 3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-caspase 8 (MBL, Nagoya, Japan), anti caspase-9 (Novus Biological, 234

Littleton, CO, USA) and anti cytochrome *c* (Upstate Biotechnology, Lake Placid, NY, USA). The membranes were washed with TBST, incubated with HRP-conjugated secondary antibody for 1 h at room temperature and washed with TBST. Proteins were detected with an enhanced ECL detection kit (New England Biolabs) and a chemiluminescence detector (LAS-1000, Fuji, Japan).

2.4. Determination of cell volume

The volume of nontreated cells was determined by calculating sphere volumes based on diameter measurement of 100 cells. Since the morphology of treated cells was not spherical, cell volume was estimated by weighing the pellet of $2\text{--}4 \times 10^6$ cells and evaluating the volume on the assumption of 1/1 w/v.

2.5. Assay for glutathione and free SH

Cells were collected (600 g, 7 min, 4°C), washed with PBS and the pellets were stored at -80°C. After protein precipitation with 5% metaphosphoric acid (0.2–0.3 ml/ 3×10^6 cells) by centrifugation (10,000g, for 30 min), the supernatant was used for GSH quantitation, and the pellet, dissolved in 0.2–0.3 ml of 0.5 M NaOH, was used for protein determination. To determine GSH in the supernatant, a glutathione assay kit (Calbiochem) was used. GSH and GSSG content were also determined by the glutathione reductase recycling assay before and after modification with 2-vinyl pyridine [35]. Samples (40 μ l) were neutralized with 2 M triethanolamine (10 μ l) in a 96-well plate. The reaction was started by adding 200 μ l per well of 0.4 U/ml enzyme in 143 mM phosphate buffer pH 7.5 containing 0.3 mM reduced nicotinamide adenine dinucleotide phosphate, 0.6 mM DTNB and 6.25 mM EDTA. The initial rate of 5-thio-2-nitrobenzoic acid formation was monitored. Determination of GSSG was done 1 h after modification of the free SH with 9 M 2-vinyl pyridine (1 μ l/well) at room temperature. Oxidized glutathione (0–6 nmol/well) served as a reference.

Total free SH content in cell extracts or in cytosolic and mitochondrial fractions (50 μ l) was determined with DTNB in a 96-well plate. Samples were acidified with 5% metaphosphoric acid (50 μ l/well) to stabilize the reduced state and neutralized with 2 M triethanolamine (50 μ l/well). DTNB (50 μ l of 1 mM solution in 50 mM phosphate buffer pH 7.2 containing 2 mM EDTA) was added. After 10 min of incubation, the absorbance was measured at 412 nm using an ELISA reader. GSH (0–20 nmol/well) precalibrated with DTNB served as a reference, using E_m 14150 M⁻¹ at 412 nm [36]. Reduction potential was calculated by using the Nernst equation for GSSG/2GSH: $E_{GSH} = E_0 - 30 \times \log \left(\frac{[GSH]^2}{[GSSG]} \right)$ [27].

2.6. Statistical analysis

Each experiment was performed at least three times, and the results were expressed as mean values \pm S.D. ($n=2\text{--}6$).

The Student *t* test was used to determine the significance of differences between the mean values obtained for the two cell lines. Otherwise, the various treatments, were analyzed using one-way analysis of variance (ANOVA) followed by either Dunnett or Bonferroni's multiple comparison test, considering $P < 0.05$ as significant.

3. Results

3.1. Allicin inhibited proliferation of HL60 and U937 cells

The proliferation rate of exponentially growing HL60 and U937 cells in the presence of allicin was determined at a density of 100,000 cells ml⁻¹. Cells were incubated with increasing concentrations of allicin (HL60: 0–10 μ M; U937: 0–30 μ M) for growing time periods up to 72 h. Cell viability was determined by the trypan blue dye exclusion assay. Allicin inhibited cell growth in a concentration-dependent manner (Figs. 1A and 2A for HL60 and U937, respectively). In the presence of 5 μ M allicin, HL60 cells exhibited about 50% inhibition of proliferation after 22 h, and at 10 μ M allicin after 22 h, the rate of inhibition reached 80% (Fig. 1A). HL60 cells were more sensitive to allicin than U937 cells. Inhibition of U937 cell proliferation reached 50% and 60% at 15 and 20 μ M allicin, respectively, after 22 h (Fig. 2A). We therefore chose to continue the study of HL60 and U937 cells (100,000 cells/ml) at 5 and 20 μ M allicin, respectively.

3.2. Allicin induced apoptosis in the cells

3.2.1. Morphological changes

Morphological changes indicating apoptotic processes were observed by staining the cells with Hoechst 33342. Distinct nuclear condensation was observed in HL60 cells treated with allicin (5 μ M) for 16 h (Fig. 1B) and U937 cells treated with allicin (20 μ M) for 40 h (Fig. 2B). In both allicin-treated cell lines, more than 90% of the cells showed blebbing after 2 h (Fig. 3A, lower panel).

3.2.2. DNA fragmentation

A DNA ladder appeared in allicin (5 μ M)-treated HL60 cells 6 h after treatment, whereas in allicin (20 μ M)-treated U937 cells, it appeared only after 40 h (Figs. 1C and 2C).

3.2.3. Cytochrome *c* release into cytoplasm and activation of caspases

To better understand the mechanism of allicin-induced apoptosis, Western blot analysis was used to detect apoptosis-related proteins. Increased amounts of cytochrome *c* appeared in the cytosol of allicin (5 μ M)-treated HL60 cells after 2.5 h of incubation. An increase in cleaved caspase 9 appeared 4 and 6 h after adding allicin, and it gradually decreased to the basal level after 30 h. Cleaved caspase 3 appeared after 16 h and was still observed 30 h after the treatment (Fig. 3B). U937 cells reacted at a slower rate to allicin (20 μ M) treatment. Cytochrome *c* release into the cytosol began 6 h after adding allicin and reached a maximal




Fig. 1. Effect of allicin on cell growth of human leukemia HL60 cells. (A) Growth dependent of HL60 cells on allicin concentration. Viable cells were counted at various time intervals between 0–72 h after staining with trypan blue. Data represent the mean value of % viable cells (nontreated=100%)±S.D. (B) Apoptotic changes observed after Hoechst 33342 (5 µg/ml) staining for 30 min. Cells were treated with 5 µM allicin for 16 h. (C) Nucleosomal DNA fragmentation of nontreated cells and allicin-treated HL60 cells (5 µM, 6 h, 5 µg/lane). Lane M is a DNA size marker.




Fig. 2. Effect of allicin on cell growth of human leukemia U937 cells. (A) Growth dependence of U937 cells on allicin concentration. Viable cells were counted at various time intervals between 0–72 h after staining with trypan blue. Data represent the mean value of % viable cells (nontreated=100%)±S.D. (B) Hoechst 33342 (5 µg/ml) staining for 30 min of cells treated with 20 µM allicin for 40 h. (C) Nucleosomal DNA fragmentation of nontreated cells and allicin-treated U937 cells (20 µM, 40 h, 10 µg/lane). Lane M is a DNA size marker.




Fig. 3. (A) Morphological changes in HL60 and U937 cells treated with allicin. HL60 and U937 cells treated with allicin (5 or 20 μ M, respectively) for 2 h were collected and washed with PBS. Cells were visualized by confocal microscopy (original magnification $\times 40$). (Upper panel) Nontreated cells (the diameter of 100 cells was measured). (Lower panel) Allicin-treated cells. (B) Immunoblot analysis of extracts (20 μ g protein/lane) from allicin treated HL60 cells at various time of allicin (5 μ M) treatment. The degrees of cytochrome *c* release into the cytosol and of caspase 9 and caspase 3 activation were assessed. β -Actin served as a control to the amount of loaded protein. The analysis of caspase 3, 9 and β -actin was done on the same blot after stripping. The data were obtained from one representative experiment (total of three independent experiments). (C) Staining of HL60 cells with MitoTracker Red CMXRos. HL60 cells treated with allicin (5 μ M, 6 h) were collected, resuspended in fresh medium and were stained for 30 min with MitoTracker Red CMXRos (0.05 μ M, 30 min). After washing twice with PBS, cells were examined by fluorescence microscopy (original magnification $\times 40$).

338 level after 18 h. The band of cleaved caspase 9 appeared at
 339 24 h, reached a maximal intensity at 48 h and was still seen at
 340 72 h. Cleaved caspase 3 appeared at 30 h, became intense at
 341 48 h and did not fade after 72 h (data not shown). Cleaved
 342 caspase 8 was not observed in either cell line after allicin
 343 treatment (data not shown).

3.2.4. Impaired mitochondrial activity

344

Mitochondrial activity was monitored with the XTT
 345 assay in cells treated with allicin (5 and 20 μ M for HL60
 346 and U937, respectively) for 16 h (Fig. 4). Both cell lines
 347 behaved similarly, showing a residual mitochondrial
 348 activity 65 \pm 5% in HL60 and 62 \pm 5% in U937 cells. At
 349




Fig. 4. (A) Allucin effect on cell viability in the absence or presence of *N*-acetyl cysteine. HL60 and U937 cells (100,000 cells/ml) were treated with allucin (5 or 20 μM, respectively) for 16 h, in the absence or presence of *N*-acetyl cysteine at 0.1, 0.5 and 1.0 mM. Cell viability was measured by the XTT assay after 3 h of incubation at 37°C with 5% CO₂. Means±S.D. of one experiment (*n*=6) are shown (total of three independent experiments). ***P*<0.01 represents a significant difference from nontreated cells, based on one-way ANOVA followed by Dunnett's test. (B) Allucin effect on HL60 cell viability following a 1-h CsA (5 μM) pretreatment. HL60 cells (100,000 cells/ml) were treated with or without allucin (5 μM) for 16 h. Cell viability was measured by the XTT assay. Means±S.D. of one experiment (*n*=6) are shown (total of three independent experiments). ****P*<0.001, represents significant difference compared with nontreated cells by one-way ANOVA followed by Bonferroni's multiple comparison test.

in U937 cells and suggest a higher resistance to allucin. 360
When cells were treated with allucin in the presence of 361
NAC (0.1–1.0 mM), mitochondrial metabolic activity was 362
not impaired, and the antiproliferative effect of allucin was 363
precluded (Fig. 4A). 364

3.3. Allucin induces changes in mitochondrial membrane potential 365

Nontreated cells showed strong staining with MitoTracker 367
Red CMXRos, indicating the negative membrane potential of 368
the mitochondria and the accumulation of the lipophilic dye. In 369
HL60 cells treated with allucin (5 μM, 6 h) the staining intensity 370
decreased significantly, indicating changes in the mitochon- 371
drial membrane potential (Fig. 3C). Reduced mitochondrial 372
staining in allucin-treated (20 μM) U937 cells occurred much 373
slower; changes were observed 24 h after treatment, and the 374
decline continued up to 40 h (data not shown). 375

A deeper insight into the involvement of mitochondrial 376
permeability transition pore (mPTP) in the cytotoxicity of 377
allucin was gained by using cyclosporine A (CsA), an 378
inhibitor of adenine nucleotide translocator. HL60 cells were 379
preincubated with 5 μM CsA for 1 h and then treated with 380
allucin for 16 or 20 h. CsA inhibited the detrimental effects of 381
allucin on cell viability as determined by the XTT assay 382
(~80% residual viability for CsA pretreatment; ~50% for 383
allucin alone). There was no significant difference between 384
nontreated and CsA-treated cells (*P*>0.05). No significant 385
difference was found between CsA alone and CsA followed 386
by allucin treated cells (*P*>0.05) (Fig. 4B). CsA-pretreated 387
cells were stained with Hoechst 33342 and MitoTracker Red 388
CMXRos. CsA pretreatment prevented the nuclear con- 389
densation induced by treatment with allucin alone (Fig. 5). 390
Mitochondrial staining also showed the preventive effect of 391
CsA, whereby allucin-induced mitochondrial membrane 392
depolarization was inhibited. 393

FACS analysis of HL60 cells treated with allucin (5 μM, 394
20 h) showed that 35.0% of the cells were apoptotic, whereas 395
CsA pretreatment reduced the apoptotic fraction to 17.1% 396
(*P*<0.05). Cell arrest at G₂ was increased in allucin-treated 397
cells with or without CsA pretreatment — 34.9% and 59.0%, 398
respectively (Fig. 6). The fraction of HL60 cells at the G₂ 399
stage was 17.3% for nontreated cells and 18.9% for cells 400
treated with CsA only (the difference is not significant). 401

3.4. Differences in GSH levels between HL60 and U937 402

GSH concentrations (nmol/total cell volume) in non- 403
treated HL60 and U937 cells were almost the same: 3.4±0.48 404
mM and 3.7±0.55 mM, respectively. However, due to the 405
differences in cell size between the two cell lines, analysis of 406
GSH concentration expressed as a function of protein levels 407
or cell numbers was also used. This analysis revealed 408
significant differences between the GSH concentrations in 409
the two cell lines. In nontreated HL60 cells, GSH concentra- 410
tion was 20.94±3.15 nmol/mg protein, and in nontreated 411
U937 cells, 30.80±6.04 nmol/mg protein (*P*<0.02). The 412

350 this stage, the drop in mitochondrial activity was not
351 accompanied by a significant change in cell number. Such
352 a change was observed only after 24 h. Nontreated HL60
353 cells proliferated at a higher rate than nontreated U937
354 cells. Although after 24 h nontreated HL60 cells exceeded
355 nontreated U937 cells in number, mitochondrial activity
356 (measured by XTT assay) in U937 cells (0.869±0.025 OD
357 units at 450 nm, *n*=6) was significantly higher than that in
358 HL60 cells (0.498±0.073 OD units, *n*=6) (*P*<0.001). These
359 results indicate a higher battery of mitochondrial enzymes

HL60




Fig. 5. Morphological effects of alliin on CsA pretreated HL60 cells. Cells (200,000 cells/ml) with or without CsA pretreatment (5 μ M, 1 h) were diluted and incubated in the presence or absence of alliin (5 μ M) for 16 h. Cells were stained with Hoechst 33342 (5 μ g/ml) or with Mito-Tracker Red CMXRos (50 nM) for 30 min. Cells were washed twice with PBS and examined by fluorescence microscopy. (A) HL60 nontreated. (B) CsA-treated. (C) Alliin-treated. (D) CsA- and alliin-treated.

413 difference was found to be even higher when cell numbers
414 were considered, GSH concentration in HL60 cells was
415 3.7 ± 0.56 nmol/ 10^6 cells whereas, in U937 cells, approxi-
416 mately twice as much [7.7 ± 1.08 nmol/ 10^6 cells ($P < 0.01$)].

417 3.5. Alliin-induced GSH depletion

418 Alliin treatment of HL60 cells caused a rapid decrease in
419 GSH concentration, reaching its lowest point at about 30 min.
420 A spontaneous recovery occurred, reaching the basal level of
421 GSH (Fig. 7A). The highest GSH levels were observed in
422 HL60 cells between 2–24 h after adding alliin. In alliin-
423 treated U937 cells, a decrease in GSH levels to a minimal
424 value occurred 2–4 h after treatment, and it was followed by a
425 gradual increase to the basal GSH level (Fig. 7B).

3.6. Alliin-induced GSH depletion in the cells pretreated with BSO

In HL60 cells treated with BSO, an inhibitor of γ -428
glutamyl-cysteine synthetase (GGCS) (0.4 mM, 20 h) GSH 429
levels decreased to 1.45 ± 0.25 nmol/ 10^6 cells. No cell death 430
was observed, but there was a slight decrease in the 431
proliferation rate ($\times 1.7$ after 20 h as compared to $\times 2.1$ in 432




Fig. 6. Cell cycle analysis of alliin-treated HL60 cells. Cells (200,000 cells/ml, 1.5×10^6) with or without CsA pretreatment (5 μ M, 1 h) were diluted and incubated in absence or presence of alliin (5 μ M) for 20 h. The cells were stained with propidium iodide in the presence of RNase A and Triton X-100, as described in Materials and methods. The data represent one experiment (total of three independent experiments).




Fig. 7. Time-dependent decrease of GSH levels in alliin-treated HL60 and U937 cells after BSO pretreatment. Cells were pretreated with or without 0.4 mM BSO for 20 h. HL60 and U937 cell cultures were diluted to 100,000 cells/ml and were grown in the presence of alliin (5 and 20 μ M, respectively). At each time point, 30-ml samples were harvested and washed twice with PBS. Cell pellets were extracted with 5% metaphosphoric acid and analyzed for GSH content and protein concentration. Means \pm S.D. of one representative experiment (total of three independent experiments).

433 nontreated cells). Alliin (5 μ M) applied to HL60 cells
 434 pretreated with BSO (0.4 mM, 20 h) caused an additional
 435 GSH decrease to 0.65 ± 0.13 nmol/10⁶ cells after 1 h (Fig. 7A,
 436 black column). There was no recovery of GSH as in the case
 437 of HL60 cells treated with alliin alone. In U937 cells
 438 pretreated with BSO (0.4 mM, 20 h), GSH levels decreased
 439 to 1.06 ± 0.14 nmol/10⁶ cells. Also, in this case, no cell death
 440 was observed and cells were still proliferating. When BSO-
 441 pretreated U937 cells were incubated with alliin (20 μ M),
 442 GSH levels further decreased to 0.33 ± 0.08 nmol/10⁶ cells
 443 within 2 h (Fig. 7B, black column). A high rate of cell death
 444 (60–80%) occurred in both cell lines 24 h after alliin was
 445 applied to the culture.

446 3.7. Reduction potential in alliin-treated cells

447 Since alliin-treated cells lost their spherical structure and
 448 their volume could not be calculated from diameter
 449 measurement, we had to use another parameter to calculate

changes in the intracellular reducing state resulting from 450
 451 fluctuations in 2GSH/GSSG ratios. Based on the assumption
 452 that 1-mg cell pellet is equivalent to 1 μ l of volume, cell
 453 pellets were weighed, and GSH molar concentration was
 454 calculated accordingly (GSH amount/cell weight). There-
 455 fore, calculated reduction potential represents only approx-
 456 imate values. The intracellular pH of HL60 cells is 7.0 [37],
 457 and the reported E_0 for this pH is -240 mV [27]. Using the
 458 above E_0 values, reducing potential (E_{GSH}) calculated for
 459 nontreated HL60 was -207 mV (GSH 3.42 ± 0.18 mM,
 460 GSSG 0.15 ± 0.023 mM) and for alliin-treated (0.5 h) -169
 461 mV (GSH 1.4 ± 0.17 mM, GSSG 0.46 ± 0.082 mM). The
 462 intracellular pH of U937 cells is 7.04 [38] or 7.2 [39], and the




Fig. 8. Free SH contents in cytosolic and crude mitochondrial fractions from alliin-treated HL60 cells. Alliin (5 μ M) was added to cells growing at density of 100,000 cells/ml. At various intervals, 100-ml samples were harvested at 4°C, washed twice with PBS and stored at -80° C overnight. Cell fractionation was done as described in Materials and methods. Total free SH and protein concentrations were determined as described in Materials and methods. The SH content at various time intervals in the cytosol (upper panel) and in the crude mitochondrial fraction (lower panel) are shown. Means \pm S.D. of one representative experiment (total of three independent experiments) [40].

463 reported E_0 values are -240 mV or -252 mV, respectively.
464 The calculated reducing potential values of nontreated U937
465 cells were -206 mV or -218 mV (GSH 3.7 ± 0.21 mM, GSSG
466 0.18 ± 0.040 mM), and for allicin-treated cells (2 h), -173 mV
467 or -185 mV (GSH 1.54 ± 0.042 mM, GSSG 0.41 ± 0.021
468 mM). The values obtained for nontreated cells are char-
469 acteristic of cells in proliferation/differentiation state,
470 whereas those obtained after allicin treatment are typically
471 obtained in the apoptotic state.

472 3.8. Free SH in the cytosolic and mitochondrial fractions of 473 HL60 cells

474 Total free SH concentrations were determined in the
475 cytosol and in the crude mitochondrial fractions prepared
476 from allicin-treated HL60 cells. The decrease in free SH in
477 the cytosol (Fig. 8, upper panel) was accompanied by a
478 decrease of free SH in the mitochondria (Fig. 8, lower panel).
479 Since mitochondrial GSH is supplied from the cytoplasm
480 and upon allicin treatment it was depleted in both cellular
481 compartments, it was followed by a substantial decrease in
482 the cell-reducing potential. Consequently, depolarization of
483 the mitochondrial membrane occurred and triggered a chain
484 of apoptotic events leading to cell death.

485 4. Discussion

486 GSH, cysteine and accessible free SH groups of various
487 proteins and peptides are rapidly oxidized by allicin to their
488 respective allyl-SS derivatives [19,22]. The mixed disulfide
489 formed is less active than allicin, yet it can easily react with
490 free SH in thiol-disulfide exchange reactions, and produce, at
491 the end of a series of reactions, the oxidized form of
492 glutathione (GSSG), the oxidized form of cysteine (cystine)
493 and glutathiolated S proteins. The leaving group (allyl-
494 mercaptan) is volatile and rapidly disappears.

495 Glutathione is the major regulator of the thiol-disulfide
496 redox state of living cells (reviewed in Refs. [29,41-43]).
497 Alterations in cellular free thiols have already been
498 described as a key event in the generation of apoptosis
499 (reviewed in [44,45]).

500 In this study, allicin induced mitochondrial release of
501 cytochrome *c*, activation of caspase 9 and 3 and DNA
502 fragmentation in HL60 and U937 cell lines in a concentra-
503 tion- and time-dependent manner. GSH depletion had been
504 shown to be associated with cell surface blebbing in
505 hepatocytes [46]. Here, cell blebbing occurred in both
506 HL60 and U937 cells treated with allicin. The rate of free SH
507 depletion from the cytosol and the mitochondria was similar,
508 indicating that allicin penetrated the mitochondria and the
509 cell membrane equally well and reacted with free SH in both
510 compartments. Allicin induced an initial drop in GSH levels
511 that was followed by a regeneration process, occurring
512 several hours after treatment. This may be due to decreased
513 feedback inhibition of GSH biosynthetic enzymes such as
514 GGCS by GSH [45]. Conversely, in BSO-pretreated cells,

there was no recovery of GSH after its allicin-induced
depletion, as BSO is a direct inhibitor of GGCS. BSO
pretreatment in allicin-treated U937 cells shortened the life
span from 72 to 20 h, indicating that preliminary GSH
depletion renders cells more sensitive to apoptosis. BSO-
depleted GSH levels in U937 cells were, at this stage, similar
to the inherent GSH level in HL60 cells and, hence, a similar
degree of sensitivity to allicin.

522 Here, we have shown that allicin causes GSH depletion
523 concomitantly in the cytosol and the mitochondria in HL60
524 cells. It is known that active GSH uptake by intact
525 mitochondria occurs even at very low cytosolic GSH levels
526 and that the rate of mitochondrial GSH depletion is much
527 slower than that of the cytosol [47]. These are indications
528 that mitochondria have more than one control mechanism to
529 maintain GSH levels. Since BSO-induced depletion of GSH
530 levels caused neither mitochondrial permeability transition
531 nor apoptosis, it is likely that BSO treatment depletes GSH
532 mainly from the cytosol, whereas allicin induced depletion
533 of mitochondrial GSH trigger the apoptotic process. More-
534 over, CsA (mPTP inhibitor) pretreatment of HL60 cells
535 inhibits allicin-induced mitochondrial permeability transi-
536 tion and cell death, corroborating the central role of
537 mitochondria in the apoptotic process induced by allicin.
538 Simultaneous addition of NAC and allicin to cells provided
539 protection against the apoptotic damage. NAC sequestered
540 the harmful activity by competing with GSH for the reaction
541 with allicin.

542 The following allicin-induced apoptotic scenario can be
543 deduced from this study: Allicin penetrates the cells and
544 readily reacts with any exposed SH present in its vicinity. As
545 GSH is the most abundant thiol molecule in the cytosol and
546 the mitochondria, it is the main target for allicin reaction. The
547 reaction with glutathione leads to an immediate change in the
548 ratio GSH/GSSG. The increased concentration of GSSG and
549 the depletion of GSH brings about a decrease in the cellular
550 reduction potential state. Concomitantly, mitochondrial
551 damage occurs, as is evident from changes in membrane
552 potential, its decreased enzymatic activity and the release of
553 cytochrome *c* to the cytosol. Upon its release, cytochrome *c*
554 participates in the activation of the caspase 9, followed by
555 activation of caspase 3.

556 Allicin induced cell cycle arrest at G2/M in HL60 cells
557 (~35%). Upon CsA pretreatment, the percentage of cells at
558 G2/M was even higher (~59%). After pretreatment of HL60
559 cells with CsA and 40-h incubation with allicin, there was no
560 change in the number of viable cells, neither were there signs
561 of cell breakage. By using CsA, it could be shown that the
562 effect of allicin on cell cycle arrest was independent of its
563 proapoptotic activity. The mechanism by which allicin
564 induces G2/M cell arrest is not clear, but a clue may reside
565 in its ability to inhibit microtubule assembly. It had been
566 shown that microtubule assembly is disrupted by direct
567 modification of tubulin SH groups [48-50] and that adding
568 GSH to an in vitro microtubule assembly system disrupted
569 by SH modification restores tubulin polymerization [51]. 570

571 Here we have shown that, in allicin-treated cells, there is an
572 increase in GSH synthesis. Therefore, cell cycle arrest would
573 be expected to expire after tubulin recovery. However, the
574 protracted G2/M phase induced by cyclosporine A and
575 allicin suggests an additional modification of a critical
576 pathway that needs an extended period to regenerate.

577 Allicin disappears from the medium very rapidly due to
578 its penetration into the cells and its reaction with SH group.
579 When applied to HL60 cells ($5 \mu\text{M}/10^5$ cells/ml) or to U937
580 cells ($20 \mu\text{M}/10^5$ cells/ml), it could not be detected in the
581 medium after 2 h or 6–8 h in HL60 or U937 cells,
582 respectively. The consumption of allicin within such a short
583 time enables full activity of SH-dependent apoptotic
584 enzymes such as the cysteine proteases and caspases 9
585 and 3 [52].

586 Cell sensitivity to allicin was shown to be dependent on
587 the intracellular content of GSH. Since there is a significant
588 difference in cell size between the two cell lines examined,
589 comparing GSH amount/cell number showed that HL60
590 cells contained $3.7 \text{ nmol GSH}/10^6$ cells, whereas U937 cells
591 contained $7.7 \text{ nmol GSH}/10^6$ cells. The differences in GSH
592 intracellular content reflect differences in sensitivity to
593 allicin. The higher the GSH, the less sensitive to allicin
594 cells are, and the slower the apoptotic signs appear.

595 The allicin-induced decrease in GSH levels modulates the
596 redox state of cells. In allicin-treated HL60 cells, the ratio of
597 [GSH]/[GSSG or GSSA] changed within the first 30 min and
598 the reducing potential reached -170 mV , whereas in U937
599 cells, it took 2 h to reach the same level. Such a high value is
600 typical of the apoptotic state [27].

601 Since GSSA (the first main product of allicin reaction
602 with GSH) is able to prevent the formation of free radicals
603 [19], it is likely that the initial event inducing apoptosis does
604 not occur via the generation of reactive oxygen species but
605 rather through mitochondrial membrane depolarization or
606 through a more finely tuned event mediated by protein
607 modification upon creating a mixed disulfide [19,53].
608 Oxidative stress incurred by the accumulation of peroxides
609 is a secondary event probably happening after the short-lived
610 GSSA is eliminated from the cells.

611 It was reported that, in BSO-treated U937 cells, the
612 depletion of GSH and the release of cytochrome *c* into the
613 cytosol were counteracted by cell-repair systems involving
614 nuclear factor κB and heat shock proteins [54]. Our results
615 show that CsA and NAC prevented apoptosis induced by
616 allicin. Taken together, the role allicin plays may be through
617 direct modification of specific free SH in proteins, such
618 as reside in apoptotic repair system, in the mPTP [55]
619 or others.

620 Acknowledgement

621 We would like to thank Dr. A. Gross, Department of
622 Biological Regulation, Weizmann Institute of Science for
623 critical reading of the manuscript, and Mrs. Anna Gakamsky
624 for her help in the statistical analysis.

References

- 625
- [1] Stoll A, Seebeck E. Chemical investigation on alliin, the specific 626 principle of garlic. *Adv Enzymol* 1951;11:377–400. 627
 - [2] Koch HP, Lawson LD. Garlic: the Science and therapeutic application 628 of *Allium sativum* L. and related species 2nd ed. 1996 [Baltimore]. 629
 - [3] Elkayam A, Mirelman D, Peleg E, Wilchek M, Miron T, Rabinkov A, 630 et al. The effects of allicin and enalapril in fructose-induced 631 hyperinsulinemic hyperlipidemic hypertensive rats. *Am J Hypertens* 632 2001;14:377–81. 633
 - [4] Eilat S, Oestraicher Y, Rabinkov A, Ohad D, Mirelman D, Battler A, et 634 al. Alteration of lipid profile in hyperlipidemic rabbits by allicin, an 635 active constituent of garlic. *Coron Artery Dis* 1995;6:985–90. 636
 - [5] Abramovitz D, Gavri S, Harats D, Levkovitz H, Mirelman D, Miron T, 637 et al. Allicin-induced decrease in formation of fatty streaks (athero- 638 sclerosis) in mice fed a cholesterol-rich diet. *Coron Artery Dis* 1999; 639 10:515–9. 640
 - [6] Gonen A, Harats D, Rabinkov A, Miron T, Mirelman D, Wilchek M, 641 et al. The antiatherogenic effect of allicin: possible mode of action. 642 *Pathobiology* 2005;72:325–34. 643
 - [7] Lang A, Lahav M, Sakhnini E, Barshack I, Fidler HH, Avidan B, et al. 644 Allicin inhibits spontaneous and TNF-alpha induced secretion of 645 proinflammatory cytokines and chemokines from intestinal epithelial 646 cells. *Clin Nutr* 2004;23:1199–208. 647
 - [8] Agarwal KC. Therapeutic actions of garlic constituents. *Med Res Rev* 648 1996;16:111–24. 649
 - [9] Hirsch K, Danilenko M, Giat J, Miron T, Rabinkov A, Wilchek M, et 650 al. Effect of purified allicin, the major ingredient of freshly crushed 651 garlic, on cancer cell proliferation. *Nutr Cancer* 2000;38:245–54. 652
 - [10] Knowles LM, Milner JA. Possible mechanism by which allyl sulfides 653 suppress neoplastic cell proliferation. *J Nutr* 2001;131:1061S–6S. 654
 - [11] Sun L, Wang X. Effects of allicin on both telomerase activity and 655 apoptosis in gastric cancer SGC-7901 cells. *World J Gastroenterol* 656 2003;9:1930–4. 657
 - [12] Oommen S, Anto RJ, Srinivas G, Karunaganar D. Allicin (from garlic) 658 induces caspase-mediated apoptosis in cancer cells. *Eur J Pharmacol* 659 2004;485:97–103. 660
 - [13] Park SY, Cho SJ, Kwon HC, Lee KR, Rhee DK, Pyo S. Caspase- 661 independent cell death by allicin in human epithelial carcinoma cells: 662 involvement of PKA. *Cancer Lett* 2005;224:123–32. 663
 - [14] Antlsperger DSM, Dirsch VM, Ferreira D, Su JL, Kuo ML, Vollmar 664 AM. Ajoene-induced cell death in human promyeloleukemic cells does 665 not require JNK but is amplified by the inhibition of ERK. *Oncogene* 666 2003;22:582–9. 667
 - [15] Jin Z, El-Deiry WS. Overview of cell death signaling pathways. *Cancer* 668 *Biol Ther* 2005;4:139–63. 669
 - [16] Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of 670 Bax and Bcl-X1 during apoptosis. *Proc Natl Acad Sci U S A* 671 1997;94:3668–72. 672
 - [17] Wolter KG, Hsu YT, Smith A, Nechushtan A, Xi X, Youle RJ. 673 Movement of Bax from the cytosol to mitochondria during apoptosis. 674 *J Cell Biol* 1997;139:1281–92. 675
 - [18] Miron T, Rabinkov A, Mirelman D, Wilchek M, Weiner L. The mode 676 of action of allicin: its ready permeability through phospholipid 677 membranes may contribute to its biological activity. *Biochim Biophys* 678 *Acta* 2000;1463:20–30. 679
 - [19] Rabinkov A, Miron T, Mirelman D, Wilchek M, Glozman S, Yavin E, 680 et al. S-allylmercaptogluthathione: the reaction product of allicin with 681 glutathione possesses SH-modifying and antioxidant properties. 682 *Biochim Biophys Acta* 2000;1499:144–53. 683
 - [20] Xiao H, Parkin KL. Antioxidant functions of selected allium 684 thiosulfonates and S-alk(en)yl-L-cysteine sulfoxides. *J Agric Food* 685 *Chem* 2002;50:2488–93. 686
 - [21] Okada Y, Tanaka K, Sato E, Okajima H. Kinetic and mechanistic 687 studies of allicin as an antioxidant. *Org Biomol Chem* 2006;4:4113–7. 688
 - [22] Rabinkov A, Miron T, Konstantinovski L, Wilchek M, Mirelman D, 689 Weiner L. The mode of action of allicin: trapping of radicals and 690

- 691 interaction with thiol containing proteins. *Biochim Biophys Acta*
 692 1998;1379:233–44.
- 693 [23] Freeman F, Kodera Y. Garlic chemistry-stability of *S*-(2-propenyl) 2-
 694 propene-1-sulfinothioate (allicin) in blood, solvents, and simulated
 695 physiological fluids. *J Agric Food Chem* 1995;43:2332–8.
- 696 [24] Lachmann G, Lorenz D, Radeck W, Steiper M. The pharmacokinetics
 697 of the S35 labeled garlic constituents alliin, allicin and vinylthioline.
 698 *Arzneimittelforschung* 1994;44:734–43.
- 699 [25] Miron T, Mironchik M, Mirelman D, Wilchek M, Rabinkov A.
 700 Inhibition of tumor growth by a novel approach: in situ allicin
 701 generation using targeted alliinase delivery. *Mol Cancer Ther* 2003;
 702 2:1295–301.
- 703 [26] Arditti F, Rabinkov A, Miron T, Reisner Y, Berrebi A, Wilchek M,
 704 et al. Apoptotic killing of B-chronic lymphocytic leukemia tumor cells
 705 by allicin generated in situ using a rituximab–alliinase conjugate. *Mol*
 706 *Cancer Ther* 2005;4:325–31.
- 707 [27] Schafer FQ, Buettner GR. Redox environment of the cell as viewed
 708 through the redox state of the glutathione disulfide/glutathione couple.
 709 *Free Radic Biol Med* 2001;30:1191–212.
- 710 [28] Jonas CR, Ziegler TR, Gu LH, Jones DP. Extracellular thiol/disulfide
 711 redox state affects proliferation rate in a human colon carcinoma
 712 (Caco2) cell line. *Free Radic Biol Med* 2002;33:1499–506.
- 713 [29] Gilbert HF. Molecular and cellular aspects of thiol-disulfide exchange.
 714 *Adv Enzymol Relat Areas Mol Biol* 1990;63:69–172.
- 715 [30] Stoll A, Seebeck E. Allium compounds V. The synthesis of natural
 716 alliin and its three optical active isomers. *Helv Chim Acta* 1951;34:
 717 481–7.
- 718 [31] Miron T, SivaRaman H, Rabinkov A, Mirelman D, Wilchek M. A
 719 method for continuous production of allicin using immobilized
 720 alliinase. *Anal Biochem* 2006;351:152–4.
- 721 [32] Nakagawa Y, Iinuma M, Matsuura N, Yi K, Naoi M, Nakayama T,
 722 et al. A potent apoptosis-inducing activity of a sesquiterpene lactone,
 723 arucanolide, in HL60 cells: a crucial role of apoptosis-inducing
 724 factor. *J Pharmacol Sci* 2005;97:242–52.
- 725 [33] Grinberg M, Schwarz M, Zaltsman Y, Eini T, Niv H, Pietrokovski S,
 726 et al. Mitochondrial carrier homolog 2 is a target of tBID in cells
 727 signaled to die by tumor necrosis factor alpha. *Mol Cell Biol* 2005;25:
 728 4579–4590.
- 729 [34] Gornall A, Bardawill C, David M. Determination of serum proteins by
 730 means of the biuret reaction. *J Biol Chem* 1949;177:751–66.
- 731 [35] Anderson ME. Determination of glutathione and glutathione disulfide
 732 in biological samples. *Methods Enzymol* 1985;113:548–55.
- 733 [36] Riddles PW, Blakeley RL, Zerner B. Ellman's reagent: 5,5'-dithiobis
 734 (2-nitrobenzoic acid) — a reexamination. *Anal Biochem* 1979;94:
 735 75–81.
- 736 [37] Restrepo D, Kozody DJ, Spinelli LJ, Knauf PA. pH Homeostasis in
 737 promyelocytic leukemic HL60 cells. *J Gen Physiol* 1988;92:489–507.
- 738 [38] Oehler R, Zellner M, Hefel B, Weingartmann G, Spittler A, Struse HM,
 739 et al. Influence of heat shock on cell volume regulation: protection
 740 from hypertonic challenge in a human monocyte cell line. *FASEB J* 740
 1998;12:553–60. 741
- [39] Nilsson C, Kagedal K, Johansson U, Ollinger K. Analysis of cytosolic 742
 and lysosomal pH in apoptotic cells by flow cytometry. *Methods Cell* 743
Sci 2003;25:185–94. 744
- [40] Aronkar SV, Reeves EL. Mosquito control with active principle of 745
 garlic, *Allium sativum*. *J Econ Entomol* 1970;63:1172–5. 746
- [41] Powis G. Anticancer drugs acting against signaling pathways. *Curr* 747
Opin Oncol 1995;7:554–9. 748
- [42] Sies H. Glutathione and its role in cellular functions. *Free Radic Biol* 749
Med 1999;27:16–21. 750
- [43] Moran LK, Gutteridge JM, Quinlan GJ. Thiols in cellular redox 751
 signalling and control. *Curr Med Chem* 2001;8:763–72. 752
- [44] Meister A. Glutathione metabolism. *Methods Enzymol* 1995;251:3–7. 753
- [45] Lash LH. Mitochondrial glutathione transport: physiological, patho- 754
 logical and toxicological implications. *Chem Biol Interact* 2006;163: 755
 54–67. 756
- [46] Jewell SA, Bellomo G, Thor H, Orrenius S, Smith M. Bleb formation 757
 in hepatocytes during drug metabolism is caused by disturbances in 758
 thiol and calcium ion homeostasis. *Science* 1982;217:1257–9. 759
- [47] Meister A. Mitochondrial changes associated with glutathione 760
 deficiency. *Biochim Biophys Acta* 1995;1271:35–42. 761
- [48] Kuriyama R, Sakai H. Role of tubulin-SH groups in polymerization to 762
 microtubules. Functional-SH groups in tubulin for polymerization. *J* 763
Biochem (Tokyo) 1974;76:651–4. 764
- [49] Li M, Ciu JR, Ye Y, Min JM, Zhang LH, Wang K, et al. Antitumor 765
 activity of Z-ajoene, a natural compound purified from garlic: 766
 antimitotic and microtubule-interaction properties. *Carcinogenesis* 767
 2002;23:573–9. 768
- [50] Xiao D, Pinto JT, Soh JW, Deguchi A, Gundersen GG, Palazzo AF, et 769
 al. Induction of apoptosis by the garlic-derived compound *S*- 770
 allylmercaptocysteine (SAMC) is associated with microtubule depo- 771
 lymerization and c-Jun NH(2)-terminal kinase 1 activation. *Cancer Res* 772
 2003;63:6825–37. 773
- [51] Nishida E, Kobayashi T. Relationship between tubulin SH groups and 774
 bound guanine nucleotides. *J Biochem (Tokyo)* 1977;81:343–7. 775
- [52] Thornberry NA. Caspases: key mediators of apoptosis. *Chem Biol* 776
Med 1998;5:R97–R103. 777
- [53] Patya M, Zahalka MA, Vanichkin A, Rabinkov A, Miron T, Mirelman 778
 D, et al. Allicin stimulates lymphocytes and elicits an antitumor effect: 779
 a possible role of p21(ras). *Int Immunol* 2004;16:275–81. 780
- [54] Filomeni G, Aquilano K, Rotilio G, Ciriolo MR. Antiapoptotic 781
 response to induced GSH depletion: involvement of heat shock 782
 proteins and NF-kappaB activation. *Antioxid Redox Signal* 2005; 783
 7:446–55. 784
- [55] McStay GP, Clarke SJ, Halestrap AP. Role of critical thiol groups on 785
 the matrix surface of the adenine nucleotide translocase in the 786
 mechanism of the mitochondrial permeability transition pore. *Biochem* 787
J 2002;367:548. 788
 789

Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome

M. Shamoto-Nagai¹, W. Maruyama¹, H. Yi², Y. Akao², F. Tribl³,
M. Gerlach⁴, T. Osawa⁵, P. Riederer³, and M. Naoi²

¹ Department of Geriatric Medicine, National Institute for Geriatrics and Gerontology, Obu, Aichi, and

² Department of Neurosciences, Gifu International Institute of Biotechnology, Kakamigahara, Gifu, Japan

³ Clinical Neurochemistry and NPF Center of Excellence Laboratories, Department of Psychiatry and Psychotherapy, and

⁴ Laboratory of Clinical Neurochemistry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany

⁵ Laboratory of Food and Biodynamics, Nagoya University Graduate School of Bioagricultural Sciences, Nagoya, Aichi, Japan

Received May 15, 2005; accepted October 20, 2005

Published online December 16, 2005; © Springer-Verlag 2005

Summary. Parkinson's disease is characterized by the selective depletion of dopamine neurons in the substantia nigra, particular those containing neuromelanin. Involvement of neuromelanin in the pathogenesis may be either cytotoxic or protective. Recently we found that neuromelanin reduces the activity of 26S proteasome. In this paper, the detailed mechanisms behind the reduced activity were studied using neuromelanin isolated from the human brain. Neuromelanin increased the oxidative stress, but synthetic melanin did not. Superoxide dismutase and deferoxamine completely suppressed the increase, indicating that superoxide produced by an iron-mediated reaction plays a central role. Iron was shown to reduce *in situ* 26S proteasome activity in SH-SY5Y cells and the reduction was protected by antioxidants. These results suggest that iron released from neuromelanin increases oxidative stress in mitochondria,

and then causes mitochondrial dysfunction and reduces proteasome function. The role of neuromelanin is discussed in relation to the selective vulnerability of dopamine neurons in Parkinson's disease.

Keywords: Neuromelanin, mitochondria, oxidative stress, Parkinson's disease, ubiquitin-proteasome system, ferrous iron.

Abbreviations

ACM 7-Aminomethylcoumarin; DCF 2',7'-Dichlorofluorescein; DFX deferoxamine mesylate; DMSO dimethyl sulfoxide; EGCG (-)-epigallocatechin gallate; GFP green fluorescent protein; H₂DCFDA 2',7'-dichlorodihydrofluorescein diacetate; MEM minimum essential medium; MG132 N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal; NAC N-acetyl cysteine; NM neuromelanin; NO[•] nitric oxide; O₂^{•-} superoxide radical;

$^{\cdot}OH$ hydroxyl radical; $ONOO^{\cdot}$ peroxy-nitrite; *PBS* phosphate-buffered saline; *PD* Parkinson's disease; *PI* propidium iodide; *PSI* carbobenzoxy-L-isoleucyl- γ -*t*-butyl-L-glutamyl-L-alanyl-L-leucinal [Z-Ile-Glu(Obu^t)-Ala-Leu-H (aldehyde)]; *SN* substantia nigra; *SOD* superoxide dismutase; *UP* ubiquitin-proteasome; *ZsGFP Zoanthus* sp. green fluorescence protein.

Introduction

In Parkinson's disease (PD), degeneration of dopamine neurons in the substantia nigra (SN) and accumulation of typical inclusion bodies, Lewy bodies, are characteristic pathological features. In PD, dopaminergic neurons of the SN and noradrenergic neurons of the locus coeruleus (LC) are preferentially affected (Hirsch et al., 1988). The presence of neuromelanin (NM) in these neurons suggests that NM may be involved in their vulnerability towards insults leading to cell death (Kastner et al., 1992). NM is synthesized from quinones and semiquinones produced by enzymatic or non-enzymatic oxidation of dopamine and noradrenaline in the SN and LC, respectively. The complex polymers contain also other oxidation metabolites of dopamine and L-DOPA, cysteinyl-DOPA (Odh et al., 1994), 5-S-cysteinyl-dopamine (Zhang and Dryhurst, 1994), proteinacious components and lipids (Gerlach et al., 1995; Zecca et al., 1994, 2000; Dzierzega-Leczna et al., 2004; Fedorow et al., 2005a; Tribl et al., 2005). In addition, inorganic components, especially iron, copper and zinc are detected in NM (Bridelli et al., 1999).

The role of NM has been discussed either in a preventing or promoting way to the degeneration of nigral dopamine neurons. NM was reported to increase the vulnerability of SN neurons (Youdim et al., 1994; Offen et al., 1997), and an iron(III)-melanin complex was cytotoxic to dopaminergic neurons *in vitro* (Double et al., 2002). Increased production of reactive oxygen and nitrogen species

(ROS, RNS) was proposed to account for the cytotoxicity of NM-metal conjugates (Ben-Shachar et al., 1991). More recently NM was reported to increase the secretion of cytokines and nitric oxide (NO[•]) from microglia, which might be also related to degeneration of dopamine neurons in PD (Wilms et al., 2003). On the other hand, NM has been proposed to be neuroprotective, by scavenging redox active metals (Fe, Cu and Mn), toxic metals (Cd, Hg and Pb) (Youdim et al., 1994; Zecca et al., 1994, 2002; Double et al., 2003) and other toxins, such as 1-methyl-4-phenylpyrimidium ion (MPP⁺) (D'Amato et al., 1986) and 1,2(*N*)-dimethyl-6,7-dihydroxyisoquinolinium ion, an oxidation product of *N*-methyl-(*R*)salsolinol, an endogenous dopaminergic neurotoxin (Naoi et al., 1994). In addition, NM synthesis reduces accumulation of cytotoxic quinone produced by dopamine oxidation (Sulzer et al., 2000).

In PD, oxidative stress, mitochondrial dysfunction, excitotoxicity and inflammation have been proposed to cause the cell death in nigro-striatal dopamine neurons. Mitochondrial dysfunction results in increased oxidative stress and on the other hand, ROS and RNS induce dysfunction in mitochondrial respiratory chain, suggesting that there is a complex interrelationship between the pathogenic factors. In addition, recent evidences suggest that failure of the ubiquitin-proteasome (UP) system leads to aggregation and accumulation of abnormal proteins to form the inclusion bodies and induce neuronal cell death (Leroy et al., 1998; McNaught et al., 2002a). The UP system is now considered to contribute to the etiopathogenesis of the sporadic form of PD, in addition to the familial forms (McNaught and Olanow, 2003b). Actually, the products of genes responsible for the familial parkinsonism, α -synuclein, ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and parkin were found to co-localize with proteasomal subunits in Lewy body (Ii et al., 1997; Gai et al., 2000). "Aggresomes" formed in response to the

accumulation of abnormal proteins in neurons with reduced UP system was indicated as a precursor of Lewy body in PD (McNaught et al., 2002b).

Recently, we found that NM purified from the human reduced the activity of 26S proteasome (Shamoto-Nagai et al., 2004), both directly *in vitro* and also *in situ* and reduced the protein amounts of PA700 regulatory subunit. These results may be relevant with those found in the parkinsonian substantia nigra: the reduction in the activity of 20S proteasome and also the levels of the regulatory subunit, PA700 (19S, ATPase) and α -subunit of 20S proteasome (McNaught et al., 2003a). However, the detailed mechanism underlying the inhibition remains to be clarified.

In this paper, the effects of NM on the induction of oxidative stress were studied using mitochondria prepared from SH-SY5Y cells, and their effects on the *in situ* activity of proteasome were examined using SH-SY5Y cells transfected with a green fluorescent protein targeting to 26S proteasomes (proteasome sensor vector) (Shamoto-Nagai et al., 2003). Generation of hydroxyl radical ($\cdot\text{OH}$), nitric oxide ($\text{NO}\cdot$) and peroxynitrite (ONOO^-) was quantitatively measured by use of 2',7'-dichlorodihydrofluorescein diacetate (H_2DCFDA) (Crow, 1997). In addition, the effects of iron on the levels of oxidative modified protein, especially acrolein-protein conjugates were examined, the increase of which was confirmed in rotenone-induced UP system failure model (Shamoto-Nagai et al., 2003). The results are discussed in relation to the possible role of NM in the cell death in PD, especially about interaction among mitochondrial dysfunction, oxidative stress and deterioration of the UP system.

Materials and methods

Materials

2',7'-Dichlorodihydrofluorescein diacetate (H_2DCFDA) was purchased from Molecular Probes (Eugene, OR, USA). Synthetic melanin was prepared by peroxida-

tion of L-tyrosine with hydrogen peroxide. Deferoxamine mesylate (DFX), (-)-epigallocatechin gallate (EGCG) from green tea, and superoxide dismutase (SOD) from bovine erythrocytes were purchased from Sigma (St. Louis, MO, USA). Propidium iodide (PI) was purchased from Molecular Probes (Eugene, OR, USA). 2',7'-Dichlorofluorescein (DCF), *N*-acetyl cysteine (NAC), L-cysteine and catalase from bovine liver, minimum essential medium (MEM) and other reagents were from Wako (Kyoto, Japan), and DL- α -tocopherol from Nacalai tesque (Kyoto, Japan). NO_2/NO_3 assay kit-F (fluorometric) was purchased from Dojindo (Kumamoto, Japan). Mouse anti-acrolein antibody was purchased from NOF (Tokyo, Japan). Inhibitors of proteasome, *N*-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132) and benzoyloxycarbonyl-L-isoleucyl- γ -*t*-butyl-L-glutamyl-L-alanyl-L-leucinal (PSI, Z-Ile-Glu(OBu)-Ala-Leu-H (aldehyde)) were purchased from Peptide Institute (Osaka, Japan). Human dopaminergic neuroblastoma SH-SY5Y cells were cultured in Cosmedium-001 tissue culture medium (CosmoBio, Tokyo, Japan), supplemented by 5% fetal calf serum in an atmosphere of 95% air and 5% CO_2 .

Preparation of NM suspension

NM was isolated from the SN of neurologically normal adult individuals as previously described (Double et al., 2000). Brains were provided from the Austro-German Brain Bank in Würzburg. The use of post-mortem human brain tissue was approved by the Ethics Committee of the University Clinics of Würzburg. In brief, SN samples were homogenised in 20 ml water and centrifuged at 12000 g for 10 min. The resulting pellets were washed twice with 50 mM phosphate buffer (pH 7.4), then incubated in 50 mM Tris buffer (pH 7.4) containing $0.5 \text{ mg} \cdot \text{ml}^{-1}$ SDS at 37°C for 3 h, followed by a further 3 h incubation with addition of $0.2 \text{ mg} \cdot \text{ml}^{-1}$ proteinase K in the same buffer. The pellets were pooled and consecutively washed with saline, water, methanol and hexane. Finally, the resulting dark pellet was incubated for three periods of 8 hrs each in 150 mM EDTA (pH 7.4) before being washed twice with water and dried under vacuum.

NM was dissolved in distilled water containing 15 mM L-cysteine and 10% dimethyl sulfoxide (DMSO) (L-Cyst-DMSO solution) to be 0.5 mg/ml in the final concentration. NM suspension was sonicated for 20 min and then shaken gently for 4 days for rehydration at room temperature under protection from light.

Isolation of mitochondria from SH-SY5Y cells

Mitochondria were prepared from SH-SY5Y cells according to Desagher et al. (1999). The cells were

gathered, washed with PBS and suspended in isotonic mitochondrial buffer (210 mM mannitol, 70 mM sucrose, 1 mM EDTA and 10 mM HEPES, pH 7.5) supplemented with complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). The cells were homogenized for 20 strokes with a Dounce homogenizer, centrifuged at 500 g for 5 min, and the supernatant was centrifuged at 10 000 g for 30 min. The crude mitochondria were obtained as the pellet and suspended in PBS for following experiments.

Measurement of ROS-RNS with H₂DCFDA

The mitochondria were suspended in PBS and the production of ROS-RNS, 'OH', NO', and peroxynitrite (ONOO⁻) produced from NO' and superoxide (O₂'⁻), was quantified fluorometrically by measuring DCF produced from H₂DCFDA (Crow, 1997). H₂DCFDA was added to be 50 μM to the mitochondria suspension (20–30 μg protein in a total reaction volume of 1 ml PBS) in the presence or absence of NM suspension (1–5 μg/ml) or synthetic melanin (1–10 μg/ml) in dark at 37°C. The increase in DCF fluorescence at 504 nm with excitation at 520 nm was measured at every 30 min for 3 h in a RF-5000 spectrofluorometer (Shimadzu, Kyoto, Japan). The generation of ROS-RNS was expressed as mol DCF per min per mg protein. The effects of DFX, anti-oxidants and other agents on the increased ROS-RNS production by NM were also examined in the same way, after 15 min pre-incubation.

Assay for NO

NO is hydrolyzed into NO₂⁻ and NO₃⁻ in aqueous solution, and this assay is based on the measurement of NO₂⁻ with 2,3-diaminonaphthalene, which is produced by reduction of NO₃⁻ (Misco et al., 1993). Mitochondrial suspension (20 μg/ml) was incubated with or without NM or synthetic melanin (2.5 μg) in PBS and produced NO' was measured according to the manufacturer's instruction, and the increase in the fluorescence at 450 nm was followed with excitation at 365 nm. The amount of NO produced was quantified by comparison with the authentic NO standard, and expressed as nmol per min per mg protein.

Assay for the *in situ* activity of 26S proteasome, and apoptosis

To quantify the *in situ* proteasome activity, SH-SY5Y cells transfected with a proteasome sensor vector were prepared as described previously (Shamoto-Nagai et al., 2004). The vector was designed to express ZsGreen fluorescence protein (ZsGFP) fused to the degradation

domain of mouse ornithine decarboxylase, a specific substrate for 26S proteasome. The reduction of 26S proteasome activity was assessed by measuring the ZsGFP fluorescence accumulated in SH-SY5Y cells transfected with the proteasome sensor vector (SH-PSV cells). SH-PSV cells were cultured in 6-well poly-L-lysine coated flasks in MEM with various concentration of iron with or without 25 μM DFX or antioxidants for 20 h. The living cells were gathered, then suspended in PBS(-). The fluorescence of the cell suspension at 505 nm with excitation at 493 nm was measured in a spectrofluorometer, RF-5300 (Shimadzu, Kyoto, Japan), and expressed as arbitrary fluorescence unit per mg protein. The protein amount was measured according to Bradford (1976).

At the same time SH-PSV cells were also subjected to fluorescence augmented flow cytometry (FACS) and the native fluorescence of ZsGFP was quantified. The cells were stained with 75 μM PI solution in PBS containing 1% Triton X-100 at room temperature for 5 min in the dark, washed and suspended in PBS and subjected to FACS analysis. Cells with lower DNA content showing PI staining less than G1 were defined to be apoptotic (subG1 peak) (Eckert et al., 2001).




Fig. 1. ROS-RNS production in mitochondria. Mitochondria isolated from SH-SY5Y cells were incubated with or without NM or synthetic melanin. Generated ROS-RNS was quantitatively measured as DCF produced from H₂DCFDA and expressed as pmol/hr. The reaction mixture was composed of 1 ml PBS containing 0, 1, 2.5 μg human brain neuromelanin (NM) or 10 μg synthetic melanin in the presence or absence of mitochondria (28 μg protein). The column and bar represent the mean and SD of triplicate measurements of 3 independent experiments. *P < 0.01

Western blot analysis of acrolein-modified protein

SH-SY5Y cells were treated with 10–200 μM Fe^{2+} or Fe^{3+} in the absence or presence of 25 μM DFX for 20 h, gathered, washed with PBS, lysed in Laemmli's sample buffer (100 mM Tris-HCl containing 4% SDS, 12% β -mercaptoethanol and 20% glycerol). The sample (20 μg protein/well) was separated by 10% polyacrylamide SDS-PAGE and blotted onto PVDF membrane, then, acrolein-modified proteins were visualized using antibody against anti-acrolein antibody, as reported (Shamoto-Nagai et al., 2003).

Statistics

Experiments were repeated at least 3 times. The data was expressed as mean \pm SD and the difference was evaluated by analysis of variance (ANOVA) followed by Scheffe's F-test. A p value less than 0.05 was estimated to be statistically significant.

Results

NM increased ROS-RNS production in mitochondria

The production of $\cdot\text{OH}$, NO and ONOO^- in mitochondria was quantified fluorometrically using DCF cleaved from H_2DCFDA




Fig. 2. Effects of SOD, (–)-epigallocatechin gallate (EGCG), deferoxamine mesylate (DFX), α -tocopherol and catalase on DCF production in mitochondria prepared from SH-SY5Y cells. Mitochondria (30 μg protein) were incubated with 2.5 $\mu\text{g}/\text{ml}$ NM in PBS, and the effects of SOD (1000 units), EGCG (1 μM), DFX (1 μM), α -tocopherol (100 μM) and catalase (500 units) were examined. The column and bar represent the mean and SD of triplicate measurements of 3 independent experiments. * $P < 0.01$

as an indicator. As shown in Fig. 1, in the presence of mitochondria, NM increased DCF fluorescence in a dose-dependent way. NM alone did not increase DCF virtually at all. On the other hand, higher amount synthetic melanin did not increase ROS-RNS levels and even in the presence of mitochondria, the increase of DCF was not significant.

Effects of DFX and anti-oxidants on ROS/RNS production by NM in mitochondria

The nature of ROS/RNS produced in mitochondria was studied by use of anti-oxidative enzymes and antioxidants. As shown in Fig. 2, SOD, but not catalase, reduced DCF production in mitochondria

NO synthesis (nmol/min/mg protein)





Fig. 3. Human brain neuromelanin (NM) increased NO^\cdot synthesis in mitochondria prepared from SH-SY5Y cells. NO_2^- and NO_3^- produced from NO^\cdot were quantitatively measured with 2,3-diaminonaphthalene as an indicator, and expressed as nmol/min/mg protein. The amount of NO^\cdot was calculated by comparing with NO_2^- standard. I: Mitochondria suspension (20 $\mu\text{g}/\text{ml}$) alone; II: mitochondria suspension incubated with NM (2.5 μg); III: mitochondria suspension incubated with synthetic melanin (2.5 μg). The column and bar represent the mean and SD of triplicate measurements of 3 independent experiments. * $p < 0.05$

ZsGFP fluorescence (Ratio to control)



ZsGFP fluorescence (Ratio to control)




Fig. 4. Iron inhibited *in situ* activity of 26S proteasome in SH-SY5Y cells transfected with a proteasome sensor vector (SH-PSV cells). After the treatment with iron with or without deferoxamine mesylate (DFX) for 20 h, the fluorescence intensity of ZsGFP, which is coded by a proteasome sensor vector, at 505 nm with excitation at 493 nm was quantified and expressed as arbitrary fluorescence unit/mg protein. The column and bar represent mean and SD of 3 experiments. After the treatment with iron, the fluorescence intensity increased in a dose-dependent manner. * $p < 0.05$ compared to the control. This increase was suppressed by 25 μM DFX significantly. # $p < 0.05$ compared to the cells treated with iron without DFX. MG; SH-PSV cells treated with 0.5 μM of MG132, a proteasome inhibitor, as a positive control.

themselves. SOD, EGCG, and DFX significantly reduced the DCF production from mitochondria enhanced by NM. The reduction by SOD was most markedly, indicating that $\text{O}_2^{\cdot-}$ plays the key role in ROS-RNS production. EGCG, which preferentially scavenges NO (Akao et al., 2004), suppressed DCF production also. DFX was also potent to reduce DCF generation, suggesting the involvement of iron in the ROS-RNS production by NM. On the other hand, α -tocopherol did not affect DCF levels in mitochondria with or without NM.

Increased NO production by NM

The effects of NM and synthetic melanin on NO production were studied in mitochondria using 2,3-diaminonaphthalene as an indicator. As shown in Fig. 3, only NM increased NO level in mitochondria, whereas synthetic melanin did not affect the NO level in mitochondria.

ZsGFP fluorescence (Ratio to Control cells)




Fig. 5. Antioxidants suppressed the iron-induced inhibition of 26S proteasome activity in SH-SY5Y cells transfected with a proteasome sensor vector (SH-PSV cells). I: Control, II: treated with 100 μM Fe^{2+} , III-VII: pre-incubated with 50 μM ascorbic acid, 50 μM NAC, 0.5 μM (-)-epigallocatechin gallate (EGCG), 50 μM GSH and 50 μM of α -tocopherol, respectively for 30 min, then with Fe^{2+} for 20 h. The column and bar represent the mean and SD of 3 experiments. * $p < 0.05$ compared to the cells treated with Fe^{2+} alone




Fig. 6. The cytotoxicity of Fe^{2+} and Fe^{3+} on SH-SY5Y cells transfected with a proteasome sensor vector (SH-PSV cells). SH-PSV cells were cultured in 6-well poly-L-lysine coated flasks with $100\ \mu\text{M}$ of Fe^{2+} or Fe^{3+} for 20 h. The cells were also subjected to FACS and the native fluorescence of ZsGFP, which is coded by proteasome sensor vector, was quantified. At the same time the cells were stained PI solution and subjected to FACS analysis to quantify the apoptotic cells. The number of cells with enhanced ZsGFP were 2.1% in non-treated cells and it increased to 3.1, 3.8 and 20.8%, by $100\ \mu\text{M}$ of Fe^{2+} or Fe^{3+} , or $10\ \mu\text{M}$ of PSI, proteasome inhibitor, respectively. At the same time, apoptotic cells increased from 4.8% in control to 9.6, 7.3 and 23.7% of the total in the presence of Fe^{2+} , Fe^{3+} , and PSI, respectively




Fig. 7. Fe^{2+} treatment increased acrolein-modified protein in SH-SY5Y cells. SH-SY5Y cells were incubated with various concentrations of Fe^{2+} for 20 h, in the absence and presence of 25 μM deferoxamine mesylate (DFX). Acrolein-modified protein was detected by Western blot analysis using antibody against acrolein-protein conjugates

Effect of iron on proteasome activity and viability in SH-SY5Y cells

The effects of iron (Fe^{2+} or Fe^{3+}) on the UP system were studied using SH-PSV cells. As shown in Fig. 4, after cultured in the presence of iron for 20 h, the ZsGFP fluorescence in SH-PSV cells increased in a dose-dependency way. Fe^{2+} and Fe^{3+} increased the accumulation of ZsGFP with almost the same intensity, and DFX (25 μM) suppressed the increase in ZsGFP fluorescence. Ascorbic acid, NAC, reduced glutathione (GSH), (-)-EGCG and α -tocopherol suppressed the accumulation of ZsGFP by Fe^{2+} (Fig. 5). On the other hand, Fe^{2+} and Fe^{3+} did not affect the *in vitro* activity of 20S proteasome samples prepared from SH-SY5Y cells (data not shown). These results show that iron inhibited the UP system, but it is not due to the direct inhibition of 20S proteasome enzymes.

The cytotoxicity of Fe^{2+} and Fe^{3+} was examined by fluorescence-augmented flow cytometry (FACS) after incubated with 100 μM Fe^{2+} and Fe^{3+} for 20 h, and the number of cells with enhanced ZsGFP increased to 3.1 and 3.4% of the total cells from 2.1%

in control, whereas 10 μM PSI, a proteasome inhibitor, increased the cell number to 20.8%, as shown in Fig. 6. At the same time, apoptotic cells increased to 9.6 and 7.3% of the total cell number in the presence of Fe^{2+} and Fe^{3+} , and 23.7% in cells treated with PSI, respectively, from 4.8% in control.

Increased acrolein-modified protein by iron treatment

To estimate the effects of iron on lipid peroxidation, acrolein, one of the most reactive aldehyde, was detected with antibody against acrolein-conjugated protein. As shown Fig. 7, acrolein-adducted protein increased in the cells treated with Fe^{2+} , in a dose-dependent way. DFX reduced the amount of acrolein-modified protein significantly.

Discussion

These results clearly demonstrate that NM, in contrast to synthetic dopamine melanin without iron, increases formation of ROS-RNS and induces onset of oxidative stress in mitochondria. In this case, it should be empha-

sized that mitochondria are essentially required for the generation of ROS-RNS. In mitochondria prepared from dopaminergic SH-SY5Y cells, ROS is produced from $O_2^{\cdot-}$ via oxidative phosphorylation, while H_2O_2 , at least in part, is generated *via* oxidation of dopamine by monoamine oxidase. About RNS recent reports suggest the existence of nitric oxide synthase in mitochondria (Elfering et al., 2002). In our system using DCF, measurable ROS-RNS species were characterized as $\cdot OH$, $NO\cdot$ and $ONOO^-$, which is produced by a reaction of $NO\cdot$ with $O_2^{\cdot-}$ (Crow, 1997). DFX, an iron chelator, markedly reduced ROS-RNS production, suggesting that iron released from NM catalytically increases these kind of ROS-RNS production in mitochondria. Indeed, iron is well known to increase $\cdot OH$ synthesis from H_2O_2 by the Fenton reaction, or by the Haber-Weiss reaction by the reaction of $O_2^{\cdot-}$ and H_2O_2 (Halliwell, 1992). In the system used in this paper SOD can completely suppresses the increase in DCF by NM, but catalase did not, indicating that the role of H_2O_2 is negligible. On the other hand, we showed that NM increases NO production by mitochondria. These results indicate that NM increased $O_2^{\cdot-}$ and NO simultaneously in mitochondria and produced $ONOO^-$, which is a powerful oxidant that may decompose further to the very reactive $\cdot OH$. It is consistent with our previous data that in SH-SY5Y cells, RNS is the major source of DCF production (Maruyama et al., 2001).

The function of NM has yet to be established, but it is considered as an endogenous iron-binding molecule in pigmented neurons (reviewed in Fedorow et al., 2005b). It may therefore play a physiological role in intraneuronal iron homeostasis. Support for this theory comes from changes in NM in the PD brain where significantly less iron is bound to NM than that seen in the normal brain (Lopiano et al., 1990). This suggests that changes in iron-binding to NM result

in increased levels of intraneuronal free iron and the subsequent cell damage observed in PD. Isolated human NM consists of 2.8% iron as estimated by Mössbauer spectroscopy (Gerlach et al., 1995), while the concentration of Fe^{3+} in the SN has been estimated using electron paramagnetic resonance at 6780 ng iron/mg intact SN tissue or 11300 ng iron/mg isolated NM (Shima et al., 1997). Iron binding studies using NM isolated from the human SN demonstrated that NM contains high ($K_d = 7.18 \pm 1.08$ nM) and low-affinity binding sites ($K_d = 94.31 \pm 6.55$ nM) for Fe^{3+} (Double et al., 2003). Our recent data demonstrates that a purely Fe^{3+} signal can be measured from intact frozen SN tissue using Mössbauer spectroscopy (Double et al., 2003). The interaction of iron with NM is of interest because the behaviour of NM changes in the presence of iron; instead of inactivating free radicals, it begins to act as an effective pro-oxidant. Recent *in vitro* studies suggest that iron is releasable under certain circumstances from NM to interact in free radical-producing pathways (Double et al., 1999): In the absence of iron, isolated human NM significantly decreased membranous damage in rat cortical homogenates *in vitro* as measured by lipid peroxidation. Further when NM was added together with iron the amount of lipid peroxidation measured was significantly less than that induced by iron alone. These results support the hypothesis that NM has antioxidant properties and can protect the cell from radical-induced damage. In contrast, when iron-saturated NM was added to the membrane homogenate, cell damage was significantly increased to 264% of that induced by NM alone; this damage was significantly attenuated by the addition of the iron chelator DFX (Double et al., 1999). These data were relevant with the result that iron increased lipid peroxidation product, acrolein-modified proteins. These and the previous results support the hypothesis that NM can have a protective influence on the cell, but can be

detrimental when iron levels rise above a certain level.

Recently we found that mitochondrial dysfunction caused by rotenone, a complex I inhibitor, increased protein modification by acrolein, and reduced the activity of proteasome, through binding of aggregated oxidized protein to the catalytic site of 20S proteasome and direct adduction of acrolein to 20S proteasome itself (Shamoto-Nagai et al., 2003). More recently we found that NM inhibited the *in vitro* and *in situ* activity of 26S proteasome in SH-SY5Y cells (Shamoto-Nagai et al., 2004). The results reported here clearly show that NM is a source of cytotoxic iron and induces the onset of oxidative stress in mitochondria leading to the dysfunction. As the result, decreased ATP synthesis and enhanced oxidative stress may induce the deterioration of UP system with increased oxidative-modified proteins, such as acrolein-conjugated ones. The capacity of NM to regulate iron level in the cells may determine the vulnerability of dopamine neurons in aging and PD by initiating the malignant cycle between the mitochondrial dysfunction, increased oxidative stress and impairment of the UP system.

Acknowledgements

This work was supported by a Grant-in-Aid on Scientific Research for Young Scientists (B) for M. S. and (C) (W. M.) and (A) (W. M. and T. O.) from Japan Society for the Promotion of Science, Grant for Research on Dementia and Bone Fracture (W. M., M. N.) from the Ministry of Health, Labor and Welfare, Japan. P.R. was supported by the National Parkinson Foundation, Miami, Florida, USA.

References

- Akao Y, Seki N, Nakagawa Y, Yi H, Matsumoto K, Ito Y, Ito K, Funaoka M, Maruyama W, Naoi M, Nozawa Y (2004) A highly bioactive lignophenol derivative from bamboo lignin exhibits a potent activity to suppress apoptosis induced by oxidative stress in human neuroblastoma SH-SY5Y cells. *Bioorgan Med Chem* 12: 4791–4801
- Ben-Shachar D, Riederer P, Youdim MBH (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. *J Neurochem* 57: 1609–1612
- Bradford MM (1976) A rapid and sensitive method for quantitation of microgram quantities of protein using the principle of protein dye binding. *Anal Biochem* 72: 248–254
- Bridelli MG, Tampellini D, Zecca L (1999) The structure of neuromelanin and its iron binding site studied by infrared spectroscopy. *FEBS Lett* 457: 18–22
- Crow JP (1997) Dichlorodihydrofluorescein and dihydrodromamine 123 are sensitive indicators of peroxynitrite *in vivo*: implications for intracellular measurement of reactive nitrogen and oxygen species. *Nitric Oxide* 1: 145–157
- D'Amato RJ, Lipman ZP, Snyder SH (1986) Selectivity of the Parkinson neurotoxin, MPTP, toxic metabolite MPP⁺ binds to neuromelanin. *Science* 231: 987–989
- Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B, Martinou J-C (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. *J Cell Biol* 144: 891–901
- Double KL, Riederer P, Gerlach M (1999) The significance of neuromelanin for neurodegeneration in Parkinson's disease. *Drug News Perspect* 12: 333–340
- Double KL, Zecca L, Costi P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. *J Neurochem* 75: 2583–2589
- Double KL, Ben-Shachar D, Youdim MBH, Zecca L, Riederer P, Gerlach M (2002) Influence of neuromelanin on oxidative pathways within the human substantia nigra. *Neurotoxicol Teratol* 24: 621–628
- Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MBH, Riederer P, Ben-Shachar D (2003) Iron binding characteristics of neuromelanin of the human substantia nigra. *Biochem Pharmacol* 66: 489–494
- Dzierzega-Leczna A, Kurkiewicz S, Chodurek E, Stepien K, Wilczok T, Arzberger A, Riederer P, Gerlach M (2004) Neuromelanin of the human substantia nigra: structural investigations by pyrolysis-gas chromatography/mass spectrometry. *J Am Soc Mass Spectrometry* 15: 920–926
- Eckert A, Steiner B, Marques C, Leutz S, Roming H, Haass C, Muller WE (2001) Elevated vulnerability to oxidative stress-induced cell death and activation